Addition of drug/s to a chemotherapy regimen for metastatic breast cancer

Butters, Daria J; Ghersi, Davina; Wilcken, Nicholas; Kirk, Steven J; Mallon, Peter

doi:10.1002/14651858.cd003368.pub3

Cited by 31 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 1 ] Inspired by the success of AIDS treatment, scientists have investigated anticancer drug combinations for the treatment of various types of cancer. [ 2 ] Due to the heterogeneity of a tumor, cancer cells exist at different stages in the cell cycle. A drug cocktail, a combination of drugs with different anticancer mechanisms that have specifi c activity on cells at different growth stages and act synergistically, should exhibit superior response and patient survival rate than any single agent.…”

Section: Doi: 101002/adma201202687mentioning

confidence: 99%

Multicompartment Intracellular Self‐Expanding Nanogel for Targeted Delivery of Drug Cocktail

Bahadur

2012

Advanced Materials

View full text Add to dashboard Cite

A nano cocktail, NCPD, fabricated from a pH and redox dual responsive polymer shows a multicompartment structure. The NCPD nanogel is stable in physiological environments while intracellular spontaneous swelling and fast releasing its payload. NCPD displays much stronger synergism than its free drug counterpart, which suggests that NCPD could greatly attenuate the side effects of drug cocktails while boosting synergistic anticancer effects.

show abstract

Section: Doi: 101002/adma201202687mentioning

confidence: 99%

Multicompartment Intracellular Self‐Expanding Nanogel for Targeted Delivery of Drug Cocktail

Bahadur

2012

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Combination chemotherapy represents a mainstay treatment modality essential for improvement of survival rates in breast cancer. However, despite numerous regimens employed clinically, patient responses following polychemotherapy remain dismal . Recent molecular insights into underlying signaling pathways and networks suggest that drug synergy in combination chemotherapy may be significantly enhanced if the order of administration, scheduling, and dose duration are given proper consideration .…”

Section: Introductionmentioning

confidence: 99%

Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site‐ and Sequence‐Specific Drug Release

Ruiz–Esparza

Segura‐Ibarra

et al. 2014

Adv Funct Materials

View full text Add to dashboard Cite

Time-staggered combination chemotherapy strategies show immense potential in cell culture systems, but fail to successfully translate clinically due to different routes of administration and disparate formulation parameters that preclude a specifi c order of drug presentation. A novel platform consisting of drug-containing PLGA polymer nanoparticles, stably fashioned with a shell composed of drug complexed with cationic cyclodextrin, capable of releasing drugs time-and sequence-specifi cally within tumors is designed. Morphological examination of nanoparticles measuring 150 nm highlight stable and distinct compartmentalization of model drugs, rhodamine and bodipy, within the core and shell, respectively. Sequential release is observed in vitro, owing to cyclodextrin shell displacement and subsequent sustained release of coreloaded drug, kinetics preserved in breast cancer cells following internalization. Importantly, time-staggered release is corroborated in a murine breast cancer model following intravenous administration. Precise control of drug release order, site-specifi cally, potentially opens novel avenues in polychemotherapy for synergy and chemosensitization strategies.

show abstract

“…Although the majority of patients are diagnosed with localized tumors, more than half will be exposed to chemotherapy at some time during the course of their disease, usually with regimens that combine anthracyclines and taxanes [2]. The addition of other chemotherapy drugs to an established regimen increases tumor response, although this positive effect is offset by greater toxicity [3].…”

Section: Introductionmentioning

confidence: 99%

A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer

et al. 2011

View full text Add to dashboard Cite

Background. This prospective, controlled study evaluated the safety, tolerability, and efficacy of the mixture of botanical compounds known as LCS101 in preventing chemotherapy-induced hematological toxicity in breast cancer patients.Methods. Female patients diagnosed with localized breast cancer were randomly allocated to receive treatment with either LCS101 or placebo capsules, in addition to conventional chemotherapy. The study intervention was initiated 2 weeks prior to the initiation of chemotherapy and continued until chemotherapy was completed, with participants receiving 2 g of LCS101 capsules thrice daily. Subjects were assessed for the development of hematological and nonhematological toxicities, as well as the tolerability and safety of the study intervention.Results. Sixty-five breast cancer patients were recruited, with 34 allocated to LCS101 and 31 allocated to

show abstract

Addition of drug/s to a chemotherapy regimen for metastatic breast cancer

Cited by 31 publications

References 38 publications

Multicompartment Intracellular Self‐Expanding Nanogel for Targeted Delivery of Drug Cocktail

Multicompartment Intracellular Self‐Expanding Nanogel for Targeted Delivery of Drug Cocktail

Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site‐ and Sequence‐Specific Drug Release

A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer

Contact Info

Product

Resources

About